Volume 1, Issue 4 November 2007
Patient information leaflets (PILs) are improving in quality as a result of new legal obligations on manufacturers to test them with potential patients. User-testing makes sure that the presentation of the information enables patients to find and understand key messages for safe and effective use of the medicine. To promote this new initiative, we are publishing a series of examples of best practice on our website. The latest in the series is the PIL for Andropatch, a transdermal delivery system of testosterone for androgen deficiency.
Article citation: Drug Safety Update November 2007, vol1 issue 4: 11b.